<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002196</url>
  </required_header>
  <id_info>
    <org_study_id>278A</org_study_id>
    <secondary_id>1012-005</secondary_id>
    <nct_id>NCT00002196</nct_id>
  </id_info>
  <brief_title>A Study of CI-1012 in HIV-Infected Patients</brief_title>
  <official_title>A Phase I Multiple Oral, Rising-Dose, Tolerance and Pharmacokinetic Trial of CI-1012 in HIV-1-Infected Volunteers.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Parke-Davis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to see if it is safe and effective to give CI-1012 to
      HIV-infected patients who do not have any symptoms of the disease. This study also examines
      how the body handles CI-1012.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients
      entered at each dose level studied.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment>32</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CI-1012</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients must have:

          -  Serologic evidence of infection with HIV-1.

          -  CD4+ cell count &gt;= 200 cells/mm3.

          -  HIV-1 RNA &gt;= 10,000 copies/ml.

        Exclusion Criteria

        Co-existing Condition:

        Patients with the following conditions are excluded:

        Viral, fungal, or bacterial infection requiring therapy other than topical medications.

        Concurrent Medication:

        Excluded:

          -  Prophylactic systematic antibacterial, antifungal or antiviral agents.

          -  Antiretroviral therapy. NOTE:

          -  Patient must be willing to remain off antiretroviral therapy for 1 week after
             completing study medication.

        Prior Medication:

        Excluded:

          -  Experimental therapy for &gt;= 4 weeks prior to initiation of study medication.

          -  Antiretroviral treatment for 3 weeks prior to initiation of study medication.

          -  Systemic steroids or anticancer agents for 4 weeks prior to initiation of study
             medication.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ViRx Inc</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Florida Research Initiative</name>
      <address>
        <city>Maitland</city>
        <state>Florida</state>
        <zip>32751</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Natl Institutes of Health</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <keyword>Dose-Response Relationship, Drug</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Drug Administration Schedule</keyword>
  <keyword>CD4 Lymphocyte Count</keyword>
  <keyword>Anti-HIV Agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

